Key result
Ultrathin Orsiro biodegradable polymer drug-eluting stents demonstrated comparable safety and efficacy profiles to second-generation durable polymer drug-eluting stents in patients with coronary artery disease.
Why the study?
Biodegradable polymer drug-eluting stents were developed to reduce risks like very late stent thrombosis associated with durable polymer stents, prompting a review of stent technology history, continued opportunities for improvement, and the potential benefits of the ultrathin Orsiro stent.
Does the ultrathin Orsiro biodegradable polymer drug-eluting stent improve clinical outcomes and reduce stent thrombosis compared to durable polymer stents in patients with coronary artery disease?
Does the ultrathin Orsiro biodegradable polymer drug-eluting stent improve clinical outcomes and reduce stent thrombosis compared to durable polymer stents in patients with coronary artery disease?
The ultrathin Orsiro biodegradable polymer drug-eluting stent offers a safe and effective alternative to durable polymer stents, with theoretical and observed benefits in reducing very late stent thrombosis and improving arterial healing.
May support Orsiro as alternative in CAD; leaves open whether biodegradable polymers reduce very late thrombosis.
Drug-eluting stents (DES) have revolutionised the treatment of coronary artery disease (CAD) in patients undergoing percutaneous coronary intervention. In recent years, there has been a focus on a new generation of DES, such as biodegradable polymer DES (BP-DES). This novel stent platform was developed with the hope of eliminating the risk of very late stent thrombosis associated with the current gold-standard durable polymer DES (DP-DES). Ultrathin Orsiro BP-DES (Biotronik, Bülach, Switzerland) are based on a cobalt-chromium stent platform that is coated with a bioresorbable polymer coating containing sirolimus. These devices have one of the thinnest struts available in the current market and have the theoretical benefit of reducing a chronic inflammatory response in the vessel wall. In 2019, the United States Food and Drug Administration (FDA) approved the use of Orsiro BP-DES in patients with CAD based on promising results in recent landmark trials, such as BIOFLOW V and BIOSTEMI. The aim of the present review article was to discuss the history of stent technology and the continued opportunities for improvements, focusing on the potential benefits of Orsiro BP-DES.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) conducted a review in Coronary Artery Disease. Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent vs. Second-generation durable polymer drug-eluting stents was evaluated. Ultrathin Orsiro biodegradable polymer drug-eluting stents demonstrated comparable safety and efficacy profiles to second-generation durable polymer drug-eluting stents in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: